Gastroesophageal Junction (GEJ) Adenocarcinoma Clinical Trials

4 recruiting

Gastroesophageal Junction (GEJ) Adenocarcinoma Trials at a Glance

10 actively recruiting trials for gastroesophageal junction (gej) adenocarcinoma are listed on ClinicalTrialsFinder across 6 cities in 22 countries. The largest study group is Phase 1 with 3 trials, with the heaviest enrollment activity in Shanghai, New York, and Durham. Lead sponsors running gastroesophageal junction (gej) adenocarcinoma studies include Astellas Pharma Global Development, Inc., Astellas Pharma Korea, Inc., and Akeso.

Browse gastroesophageal junction (gej) adenocarcinoma trials by phase

Treatments under study

About Gastroesophageal Junction (GEJ) Adenocarcinoma Clinical Trials

Looking for clinical trials for Gastroesophageal Junction (GEJ) Adenocarcinoma? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Gastroesophageal Junction (GEJ) Adenocarcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Gastroesophageal Junction (GEJ) Adenocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 3

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc.500 enrolled224 locationsNCT06901531
Recruiting
Phase 1

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Gastric AdenocarcinomaPancreatic AdenocarcinomaGastroesophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Global Development, Inc.398 enrolled45 locationsNCT05365581
Recruiting
Phase 1

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

Metastatic Solid TumorEsophageal Squamous Cell CarcinomaGastric Adenocarcinoma+2 more
Plexium, Inc.155 enrolled10 locationsNCT07284186
Recruiting

A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Korea, Inc.377 enrolled13 locationsNCT06902545
Recruiting
Phase 3

A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma

Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Akeso760 enrolled6 locationsNCT07023315
Recruiting
Phase 1

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

Gastric CancerCervical CancerCancer+7 more
Rondo Therapeutics149 enrolled2 locationsNCT07218003
Recruiting
Phase 2

An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma

Gastroesophageal Junction (GEJ) Adenocarcinoma
National Cancer Center Hospital East26 enrolled1 locationNCT07018570
Recruiting

Pan-tumor MRD Study

Esophageal CancerMelanoma (Skin Cancer)NSCLC (Non-small Cell Lung Cancer)+4 more
Paradigm Health1,350 enrolled2 locationsNCT06605404
Recruiting
Phase 2

Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer

Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Ruijin Hospital30 enrolled1 locationNCT07026149
Recruiting
Phase 3

M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

Locally Advanced Unresectable or Metastatic Gastric CancerLocally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
FutureGen Biopharmaceutical (Beijing) Co., Ltd486 enrolled1 locationNCT06177041